LB Pharmaceuticals Inc (LBRX): רווח נקי למניה ב-12 החודשים האחרונים
LB Pharmaceuticals Inc (LBRX) develops effective schizophrenia treatments with minimal side effects, supported by a clear capital expenditure plan for clinical trials. The rolling annual earnings per share snapshot on GURU.Markets shows that the metric value is -4.65. The company leverages its proprietary targeted molecule platform to establish a closed niche within the treatment of psychiatric disorders.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%90%D7%97%D7%AA%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_LBRX_-_LB-Pharmaceuticals-Inc_-_Net-earnings-per-one-share-for-the-last-twelve-months "רווח נקי למניה (EPS TTM) LB Pharmaceuticals Inc (LBRX): לתקופה 12.09.2025 - 13.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת LB Pharmaceuticals, Inc. (LBRX)
Investors use this metric to assess the real return of each share by dividing the total annual net income by the total number of outstanding securities. For LB Pharmaceuticals Inc (LBRX), which attracts leading chemists through stock option programs, the 12-month net income per share trend demonstrates how effectively intellectual capital is converted into profit for the shareholders of this high-risk asset.
